BTIG Research Forecasts Strong Price Appreciation for Kymera Therapeutics (NASDAQ:KYMR) Stock

Key Points

• BTIG Research raised Kymera Therapeutics’ price target to $139 from $134 and reiterated a “Buy” rating, implying 13.38% upside from the prior close.
• Analyst sentiment remains broadly positive: Kymera has a consensus “Moderate Buy” rating and an average price target of $137.32, with other targets ranging as high as $180.
• Kymera reported a quarterly loss of $1.32 per share, missing the $1.26 consensus estimate, while revenue was essentially flat year over year and the company continued to post substantial losses.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) had its price objective raised by equities research analysts at BTIG Research from $134.00 to $139.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage presently has a "buy" rating on the stock. BTIG Research's target price would indicate a potential upside of 13.38% from the company's previous close.

KYMR has been the subject of several other research reports. Loop Capital set a $132.00 target price on shares of Kymera Therapeutics in a research report on Thursday. Wolfe Research upgraded Kymera Therapeutics from a "peer perform" rating to an "outperform" rating and set a $180.00 price target for the company in a research note on Thursday, September 10th. Guggenheim boosted their price objective on Kymera Therapeutics from $135.00 to $170.00 and gave the company a "buy" rating in a report on Monday, August 31st. Oppenheimer restated an "outperform" rating and set a $140.00 price objective on shares of Kymera Therapeutics in a research note on Thursday. Finally, Wells Fargo & Company increased their target price on Kymera Therapeutics from $116.00 to $151.00 and gave the stock an "overweight" rating in a report on Thursday, August 27th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $137.32.

Kymera Therapeutics Stock Performance

Kymera Therapeutics stock traded up $0.09 during midday trading on Thursday, reaching $122.60. The stock had a trading volume of 1,045,347 shares, compared to its average volume of 748,981. Kymera Therapeutics has a twelve month low of $55.66 and a twelve month high of $130.05. The stock has a market capitalization of $10.19 billion, a PE ratio of -37.84 and a beta of 1.98. The stock's 50-day simple moving average is $114.92 and its 200 day simple moving average is $95.84.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.26) by ($0.06). Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. Kymera Therapeutics's revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.94) earnings per share. Equities analysts predict that Kymera Therapeutics will post -3.85 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Kymera Therapeutics news, insider Brian Adams sold 6,371 shares of Kymera Therapeutics stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $116.83, for a total transaction of $744,323.93. Following the transaction, the insider directly owned 50,254 shares in the company, valued at approximately $5,871,174.82. The trade was a 11.25% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $113.80, for a total value of $3,414,000.00. Following the transaction, the chief executive officer directly owned 666,568 shares in the company, valued at approximately $75,855,438.40. This trade represents a 4.31% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 15.98% of the company's stock.

Hedge Funds Weigh In On Kymera Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new stake in shares of Kymera Therapeutics in the 2nd quarter valued at $635,067,000. Merck & Co. Inc. bought a new position in Kymera Therapeutics during the second quarter worth $88,544,161. Bank of America Corp DE bought a new position in Kymera Therapeutics during the second quarter worth $43,378,000. Bank of New York Mellon Corp bought a new position in Kymera Therapeutics during the second quarter worth $24,721,000. Finally, Eagle Health Investments LP acquired a new stake in Kymera Therapeutics in the second quarter worth $19,052,000.

More Kymera Therapeutics News

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Promising KT-579 Phase 1 results: Kymera reported deep and sustained IRF5 degradation, strong modulation of disease-relevant biomarkers and a favorable safety profile in healthy volunteers. The data support further development of KT-579 as an oral treatment for immunological diseases. Kymera Therapeutics third-quarter results and KT-579 trial release
• Positive Sentiment: Analyst remains constructive: Morgan Stanley reportedly expects KYMR’s stock price to rise, providing some support for investor sentiment following the clinical update. Morgan Stanley analyst view
• Neutral Sentiment: KT-621 remains an investor focus: Preview coverage highlighted the company’s KT-621 program ahead of the earnings release, but the supplied reports do not provide new efficacy or regulatory data for the program. Kymera Therapeutics earnings preview
• Negative Sentiment: Quarterly loss exceeded expectations: Kymera reported a third-quarter loss of $1.32 per share, worse than the $1.26 consensus estimate and below the $0.94 loss recorded a year earlier. Revenue was essentially flat year over year, offering little financial offset to continued research and development spending. Kymera Therapeutics third-quarter financial results
• Negative Sentiment: Net loss widened: The broader earnings coverage reinforced the deteriorating profitability trend, with a negative net margin and no near-term earnings support. Investors may therefore remain sensitive to clinical execution, pipeline progress and cash-burn expectations. Kymera Therapeutics Q3 net loss widened

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins through targeted protein degradation. Its approach is designed to use the cell's natural protein-disposal system to remove proteins that may be difficult to address with conventional drug modalities.

The company's research and development programs have targeted a range of disease areas, including immune-mediated and inflammatory conditions, cancer, and other serious illnesses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.